Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: A retrospective analysis

Critical Care

Volumn 14, Issue 4, 2010, Pages

  Sander, Michael ^a   Spies, Claudia D ^a   Martiny, Viktoria ^a   Rosenthal, Christoph ^a   Wernecke, Klaus Dieter ^a   von Heymann, Christian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BIOLOGICAL MARKER; CREATINE KINASE; CREATINE KINASE ISOENZYME; FRESH FROZEN PLASMA; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ACUTE KIDNEY FAILURE; AGED; ANTICOAGULATION; ARTERIAL PRESSURE; ARTERY CATHETER; ARTICLE; BLOOD GAS ANALYSIS; BLOOD SAMPLING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; CENTRAL VENOUS CATHETER; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; HEART INFARCTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROLOGICAL COMPLICATION; OPEN HEART SURGERY; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RADIAL ARTERY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; STROKE; THORACOTOMY; BLEEDING; CHI SQUARE DISTRIBUTION; CONFIDENCE INTERVAL; HEART SURGERY; METHODOLOGY; POSTOPERATIVE COMPLICATION; RISK; RISK FACTOR; STATISTICAL MODEL; STATISTICS;

AGED; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; HUMANS; LOGISTIC MODELS; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANEXAMIC ACID;

EID: 77955117750     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9216     Document Type: Article

References (30)

1. Mangano D, Tudor IC, Dietzel C, . Group MSoPIR, Foundation IRaE The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006, 354:353-365. 10.1056/NEJMoa051379, 16436767, Group MSoPIR, Foundation IRaE.
2. Mangano D, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J, . Group IoTMSoPIR, Foundation IRaE Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007, 297:471-479. 10.1001/jama.297.5.471, 17284697, Group IoTMSoPIR, Foundation IRaE.
3. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006, 46:327-338. 10.1111/j.1537-2995.2006.00724.x, 16533273.
4. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008, 358:784-793. 10.1056/NEJMoa0707768, 18287601.
5. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008, 358:771-783. 10.1056/NEJMoa0707571, 18287600.
6. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R, . Investigators B A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008, 358:2319-2331. 10.1056/NEJMoa0802395, 18480196, Investigators B.
7. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008, 107:1783-1790. 10.1213/ane.0b013e318184bc20, 19020118.
8. Breuer T, Martin K, Wilhelm M, Wiesner G, Schreiber C, Hess J, Lange R, Tassani P. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg 2009, 35:167-171. author reply, 171, 10.1016/j.ejcts.2008.09.038, 19027313.
9. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010, 110:350-353. 10.1213/ANE.0b013e3181c92b23, 19996135.
10. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010, 110:21-29. 10.1213/ANE.0b013e3181c0ea6d, 19910626.
11. Calafiore AM, Teodori G, Mezzetti A, Bosco G, Verna AM, Di Giammarco G, Lapenna D. Intermittent antegrade warm blood cardioplegia. Ann Thorac Surg 1995, 59:398-402. 10.1016/0003-4975(94)00843-V, 7847955.
12. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007, CD001886.
13. Carless PA, Moxey AJ, Stokes BJ, Henry DA. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord 2005, 5:19. 10.1186/1471-2261-5-19, 1185524, 15992412.
14. Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin. Anesth Analg 2008, 107:1469-1478. 10.1213/ane.0b013e318182252b, 18931201.
15. D'Ambra MN, Akins CW, Blackstone EH, Bonney SL, Cohn LH, Cosgrove DM, Levy JH, Lynch KE, Maddi R. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996, 112:1081-1089. 10.1016/S0022-5223(96)70110-1, 8873736.
16. van-der-Meer J, Hillege HL, Ascoop CA, Dunselman PH, Mulder BJ, van-Ommen GV, Pfisterer M, van-Gilst WH, Lie KI. Aprotinin in aortocoronary bypass surgery: increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemost 1996, 75:1-3.
17. Casati V. About dosage schemes and safety of tranexamic acid in cardiac surgery. Anesthesiology 2003, 99:236. author reply, 236, 10.1097/00000542-200307000-00039, 12826869.
18. Schlag MG, Hopf R, Redl H. Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model. Neurosurgery 2000, 47:1463-1467. 10.1097/00006123-200012000-00048, 11126922.
19. Schlag MG, Hopf R, Zifko U, Redl H. Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats. Acta Neurochir (Wien) 2002, 144:63-69. 10.1007/s701-002-8275-z, 11807648.
20. Yeh HM, Lau HP, Lin PL, Sun WZ, Mok MS. Convulsions and refractory ventricular fibrillation after intrathecal injection of a massive dose of tranexamic acid. Anesthesiology 2003, 98:270-272. 10.1097/00000542-200301000-00042, 12503009.
21. Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002, 301:168-173. 10.1124/jpet.301.1.168, 11907171.
22. O'Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2: isolated valve surgery. Ann Thorac Surg 2009, 88:S23-S42. 10.1016/j.athoracsur.2009.05.056, 19559823.
23. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, Ghannam M, Yeo E, Djaiani G, Karski J. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004, 44:1453-1462. 10.1111/j.1537-2995.2004.04144.x, 15383018.
24. Sundt TM, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993, 55:1418-1424. 10.1016/0003-4975(93)91082-X, 7685587.
25. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007, 115:2801-2813. 10.1161/CIRCULATIONAHA.106.671222, 17533182.
26. Bucerius J, Gummert JF, Borger MA, Walther T, Doll N, Onnasch JF, Metz S, Falk V, Mohr FW. Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients. Ann Thorac Surg 2003, 75:472-478. 10.1016/S0003-4975(02)04370-9, 12607656.
27. Wolman RL, Nussmeier NA, Aggarwal A, Kanchuger MS, Roach GW, Newman MF, Mangano CM, Marschall KE, Ley C, Boisvert DM, Ozanne GM, Herskowitz A, Graham SH, Mangano DT. Cerebral injury after cardiac surgery: identification of a group at extraordinary risk: Multicenter Study of Perioperative Ischemia Research Group (McSPI) and the Ischemia Research Education Foundation (IREF) Investigators. Stroke 1999, 30:514-522.
28. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004, 128:442-448. 10.1016/j.jtcvs.2004.03.041, 15354106.
29. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987, 2:1289-1291. 10.1016/S0140-6736(87)91190-1, 2446091.
30. Dietrich W. Aprotinin: 1 year on. Curr Opin Anaesthesiol 2009, 22:121-127. 10.1097/ACO.0b013e32831c833f, 19295302.